Notably, melanoma patients with BRAF and NRAS mutations who have failed to respond optimally to agents like anti-PD-1 or anti-CTLA-4 antibodies have exhibited either partial response or long-stable disease (SD) after receiving TIL treatment[52]. This evidence concerns the gene CTLA4 and melanoma.